OAM
ENTA icon

Oppenheimer Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Oppenheimer Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-75
Closed -$2K – 1684
2017
Q1 		$2K Buy
+75
New +$2.34K ﹤0.01% 1636

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Oppenheimer Asset Management's ENTA Position: Q2 2017 in Review

Oppenheimer Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2017, closing a stake of 75 shares — an estimated $2K sold.

Oppenheimer Asset Management first reported a position in ENTA in Q1 2017 and held it in 1 quarter. The position peaked at $2K in Q1 2017. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2017.

  • Oppenheimer Asset Management reported no remaining Enanta Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Oppenheimer Asset Management sold 75 Enanta Pharmaceuticals shares in Q2 2017, an estimated $2K.
  • Oppenheimer Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Oppenheimer Asset Management's Enanta Pharmaceuticals position peaked at $2K in Q1 2017.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2017.

Based on Oppenheimer Asset Management's 13F filing for Q2 2017, filed 9 Aug 2017.